To print: Select File and then Print from your browser's menu

Title: New Cautions Regarding Rare Heart-Related Risks for All ADHD Drugs

"New Cautions Regarding Rare Heart-Related Risks for All ADHD Drugs"

OTTAWA, CANADA -- May 26, 2006 -- Health Canada has revised the prescribing and patient information for all drugs used for the management of ADHD (attention deficit hyperactivity disorder) and advises Canadians not to use them if they have high blood pressure, heart disease or abnormalities, hardening of the arteries or an overactive thyroid gland. The new prescribing and patient information applies to both adults and children. Standardized labeling that identifies risk factors for rare heart-related side effects, and new recommendations to physicians have been added to the prescribing information for the following drugs, and for any products containing these drugs: Adderall XR® mixed salts amphetamine extended-release Attenade™ dextromethylphenidate [approved by Health Canada, but the manufacturer has not marketed in Canada] Biphentin® methylphenidate controlled release [approved by Health Canada, but the manufacturer has not marketed in Canada] Concerta* methylphenidate extended release Dexedrine® dextroamphetamine Ritalin® methylphenidate Ritalin SR® (methylphenidate extended release) Strattera® atomoxetine * Trademark used under licence to Janssen-Ortho Inc. ADHD drugs are generally safe and provide benefits for Canadians and their treatment of ADHD when used as directed. Decisions about taking any of the drugs are best made in consultation with a physician. Before using these drugs, patients should inform their doctor if they are involved in strenuous exercise or activities, are using other drugs for ADHD, have certain heart-related conditions or have a family history of sudden cardiac death. Health Canada stresses that patients should not stop taking ADHD medication without first consulting their doctors. All ADHD drugs stimulate the heart and blood vessels (cardiovascular system). The effects are usually mild or moderate, but in some patients, this stimulation may – in rare cases – result in cardiac arrests, strokes or sudden death. Patients taking ADHD drugs should consult with their physician if they have any questions or concerns. Health Canada continues to monitor the safety of these drugs and Canadians will continue to be informed if new concerns arise. For more information, please see the Health Canada letter to healthcare professionals regarding this issue. To report a suspected adverse reaction to ADHD drugs, please contact the Canadian Adverse Drug Reaction Monitoring Program (CADRMP) of Health Canada by one of the following methods: Telephone: 866-234-2345 Facsimile: 866-678-6789 CADRMP Marketed Health Products Directorate Health Protection Building, Tunney's Pasture, AL 0701C Ottawa, ON K1A 0K9 Email: cadrmp@hc-sc.gc.ca SOURCE: Health Canada

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.